Ones To Watch News
Refine Search
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Pharmaceutical
Swedish medtech company Amferia has announced findings showing that its peptide-based hydrogel could restore the effectiveness of antibiotics against resistant bacteria. 18 November 2024
Pharmaceutical
Orano Med, a subsidiary of the Orano Group, has begun construction of an Advanced Thorium Extraction Facility (ATEF) in France. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biotechnology
Oxford, UK-based rare respiratory diseases focused AlveoGene today revealed it has been granted a Rare Pediatric Disease designation (RPDD) by the US Food and Drug Administration (FDA) for AVG-002, its novel, inhaled gene therapy for lethal neonatal surfactant protein B (SP-B) deficiency. 15 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Biotechnology
Swiss clinical-stage biopharma AC Immune saw its shares gain 8% to $3.38 in US trading this morning, after it released positive interim safety and immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056. 14 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Pharmaceutical
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Pharmaceutical
Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm MEDICE Arzneimittel Pütter. 14 November 2024
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series B financing to further advance its portfolio of clinical-stage, nutrient-stimulated hormone (NuSH) analog peptides. 14 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Privately-held Flare Therapeutics, a US biotech targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, has entered into a strategic discovery collaboration with Swiss pharma giant Roche. 14 November 2024
Biotechnology
Shares of US genetic meds company MeiraGTx Holdings were up 7% at $7.12 in early trading after it announced important developments along with its third-quarter 2024 financials, reporting a $0.54 per share loss. 13 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Pharmaceutical
The US Food and Drug Administration approved New Jersey, USA-based Insmed’s Brinsupri (brensocatib) tablets to treat non-cystic fibrosis bronchiectasis (NCFB), a chronic inflammatory lung condition, in patients ages 12 years and older. 13 August 2025
Biotechnology
Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and commercialize the US firm’s KRAS G12D inhibitor. 12 August 2025
Biotechnology
US biotech Rezo Therapeutics today announced the appointment of Derek Hicks as its chief executive (CEO). 12 August 2025
Biotechnology
UK and USA-listed PureTech Health today announced the launch of a new founded entity to be called Celea Therapeutics. 12 August 2025
Biotechnology
USA-based Bionova Scientific, a full-service contract development and manufacturing organization (CDMO) for biologics and a subsidiary of Japanese technology company Asahi Kasei, has announced the opening of a plasmid DNA (pDNA) development and production facility in The Woodlands, Texas. 12 August 2025
Biotechnology
French manufacturer Sartorius Stedim Biotech and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a partnership. 11 August 2025
Biotechnology
Denmark-based IO Biotech’s shares traded 51% higher ahead of the morning bell at $2.74 after the company said that Cylembio (imsapepimut and etimupepimut 11 August 2025
Biotechnology
The US Food and Drug Administration (FDA) has ordered label changes for bluebird bio's Skysona (elivaldogene autotemcel) due to blood cancer risks associated with the gene therapy product. 11 August 2025
Biotechnology
Indian cell therapy company Eyestem Research has raised $10 million in a significantly oversubscribed funding round to support the next stage of development for its investigational retinal pigment epithelial (RPE) cell therapy, Eyecyte-RPE. 11 August 2025
Biotechnology
US clinical-stage biotech Vor Bio has announced the appointment of Dallan Murray as chief commercial officer, effective immediately. 11 August 2025
Pharmaceutical
USA-based biotech DoveTree Medicines has signed a far-reaching partnership with Chinese drug discovery company XtalPi, in a deal worth up to $5.99 billion. 7 August 2025
Biotechnology
US artificial intelligence drug discovery firm Chai Discovery has secured $70 million in Series A funding, drawing backing from several high-profile investors as it seeks to transform how new biologic drugs are engineered. 7 August 2025
Biotechnology
Shattuck Labs yesterday announced that it has entered into a securities purchase agreement for a private placement financing 6 August 2025
Biotechnology
US cardiometabolic specialist MetaVia has announced a research collaboration with Korea’s Syntekabio, an artificial intelligence (AI)-driven drug discovery company. 5 August 2025
Biotechnology
XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday. 5 August 2025
Biotechnology
Texas, USA-based Nanoscope Therapeutics has recently submitted a rolling biologics license application (BLA) to the Food and Drug Administration (FDA) for MCO-010 (sonpiretigene isteparvovec), a novel gene therapy candidate targeting retinitis pigmentosa (RP). 5 August 2025
Biotechnology
Privately-held US clinical-stage biotech Cellergy Pharma announced the appointment Christopher Cano as chief executive (CEO). 5 August 2025
Biotechnology
Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular dystrophy (DMD) treated with Hansa’s imlifidase prior to receiving Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec-rokl) in the SRP-9001-104 trial. 4 August 2025
Biotechnology
Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double the 128.7 million euros of the same period in 2024 and way above the consensus estimate of €137.9 million euros. 4 August 2025
Biotechnology
Philadelphia, USA-based Medicus Pharma and Boston-based biotech Helix Nanotechnologies have entered into a non-binding memorandum of understanding (MoU) in respect of their shared mutual interest in the development of thermostable infectious diseases vaccines. 4 August 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze